Eli Lilly CEO says Medicare coverage of obesity drugs could 'change the game' for upcoming pill launch
Lilly CEO Dave Ricks is confident in the ability of the company's pill to compete and is preparing for a "full launch" in the second quarter.
TL;DR
- Eli Lilly CEO Dave Ricks sees Medicare coverage of obesity drugs as a key driver for the launch of orforglipron.
- Medicare coverage for obesity medicines is expected to start later this year, coinciding with the launch of orforglipron.
- Many patients currently pay cash for competitor Novo Nordisk's obesity pill.
- Lilly expects Medicare coverage to "change the game" by increasing patient access.
- The launch of orforglipron is planned for the second quarter, with full launch expected then.
- Drug pricing deals with President Trump will enable Medicare to cover obesity medicines.
- Certain Medicare patients will have a $50 monthly copay for GLP-1 drugs, including for obesity.
- An estimated 20 to 30 million Medicare beneficiaries with obesity could be eligible for these treatments.
- Drug pricing agreements include a "step down in pricing" early this year, but Ricks expects volume growth in the latter half.
- Lilly will provide financial impact details during its fourth-quarter earnings report.
- Lilly was the first drugmaker to sell obesity treatments directly to patients via LillyDirect.